CCIA
BHVN

Campbell & Co Investment Adviser’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Campbell & Co Investment Adviser’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,020
Closed -$477K – 1003
2022
Q1 		$477K Buy
+4,020
New +$501K 0.13% 294
2021
Q4 		– Sell
-2,500
Closed -$347K – 892
2021
Q3 		$347K Buy
+2,500
New +$312K 0.11% 325

Other funds holding BHVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Campbell & Co Investment Adviser's BHVN Position: Q2 2022 in Review

Campbell & Co Investment Adviser sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 4,020 shares — an estimated $477K sold.

Campbell & Co Investment Adviser first reported a position in BHVN in Q3 2021 and held it in 2 quarters. The position peaked at $477K in Q1 2022. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

  • Campbell & Co Investment Adviser reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 4,020 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $477K.
  • Campbell & Co Investment Adviser first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $477K in Q1 2022.
  • 329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2022, filed 9 Aug 2022.